Protein-bound paclitaxel

From Wikipedia, the free encyclopedia

 This article or section is in need of attention from an expert on the subject.

WikiProject Pharmacology or the Pharmacology Portal may be able to help recruit one.

If a more appropriate WikiProject or portal exists, please adjust this template accordingly.

Protein-bound paclitaxel is an injectable formulation of paclitaxel, a mitotic inhibitor drug used in the treatment of breast cancer.[1] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is sold in the United States under the trade name Abraxane by Abraxis Bioscience.[2]

This treatment was approved by the Food and Drug Administration in January 2005 for cases where cancer did not respond to other chemotherapy or has relapsed.[3]

Abraxane is a first[citation needed] in its class of drugs using nanoparticle albumin bound (nab) technology platform.nab Technology

[edit] References

  1. ^ Definition of "protein-bound paclitaxel". National Cancer Institute Dictionary of Cancer Terms.
  2. ^ Paclitaxel Albumin-stabilized Nanoparticle Formulation. National Cancer Institute Drug Information.
  3. ^ FDA Approval for Nanoparticle Paclitaxel. National Cancer Institute Drug Information.
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.